RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:53540

Goldmann-Favre syndrome

low confidenceDisorder

Also known as: ESCS · Enhanced S-cone syndrome · Retinoschisis with early nyctalopia

Publications

1,810

Trials

1

Interventional, condition-specific

Researchers

999

Distinct authors in sample

Gene link

NR2E3

Strong

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

Goldmann-Favre syndrome (GFS) is a vitreoretinal characterized by early onset of night blindness, reduced bilateral visual acuity, and typical fundus findings ( pigmentary degenerative changes, macular edema, retinoschisis).

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

enhanced S-cone syndrome 1 · retinoschisis with early nyctalopia

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Strong — NR2E3

  2. LiteraturePresent

    1,810 matched papers (1,097 in last 10 years) Source

  3. Phenotype characterisedPresent

    9 HPO annotations (e.g. Undetectable electroretinogram; Retinoschisis; Nyctalopia) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    1 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (NR2E3).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

9

Associated phenotypes · MONDO:0100289

  • Undetectable electroretinogram
  • Retinoschisis
  • Nyctalopia
  • Edema
  • Cataract

Showing 5 of 9 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

1,810

1,810 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

1,810 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,097 in the last 10 years · low confidence

Phrase hits: 546 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

999

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Banin E6 papers · 2026

    Department of Ophthalmology, Hadassah Medical Center, Jerusalem, Israel.

    Papers in Europe PMC
  2. 02
    Audo I5 papers · 2026

    Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris 75012, France isabelle.audo@inserm.fr.

    Papers in Europe PMC
  3. 03
    Fujinami K5 papers · 2026

    Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo 152-8902, Japan.

    Papers in Europe PMC
  4. 04
    Marques JP5 papers · 2026

    Centro de Responsabilidade Integrado de Oftalmologia do Centro Hospitalar e Universitário de Coimbra, EPE (CRIO-CHUC), Coimbra, Portugal.

    Papers in Europe PMC
  5. 05
    Sharon D5 papers · 2026

    Ocular Molecular Genetics Institute and the Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston 02114, USA.

    Papers in Europe PMC
  6. 06
    Stone EM5 papers · 2025

    Institute for Vision Research, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA 52241, USA. edwin-stone@uiowa.edu.

    Papers in Europe PMC
  7. 07
    Wang Y5 papers · 2025

    McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI, USA.

    Papers in Europe PMC
  8. 08
    Aísa-Marín I4 papers · 2023

    Departament of Genetics, Microbiology and Statistics, Avda. Diagonal 643, Universitat de Barcelona, Barcelona 08028, Spain; CIBERER, ISCIII, Universitat de Barcelona, Barcelona, Spain; Institute of Biomedicine (IBUB, IBUB-IRSJD), Universitat de Barcelona, Barcelona, Spain.

    Papers in Europe PMC
  9. 09
    Bohrer LR4 papers · 2025

    Institute for Vision Research, Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA 52241, USA. laura-bohrer@uiowa.edu.

    Papers in Europe PMC
  10. 10
    Chan CM4 papers · 2026

    School of Pharmacy, University of Nottingham, Nottingham, UK.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

1

interventional trials for this specific condition

1 interventional trial matched this specific condition name; none in our sample are currently recruiting.

Data as of 11 September 2026 · last trial check 28 July 2026

1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).

low confidence · 80.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

1 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Goldmann-Favre syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Goldmann-Favre syndrome" OR "Enhanced S-cone syndrome" OR "Retinoschisis with early nyctalopia" OR "enhanced S-cone syndrome 1") OR ("NR2E3" OR "NR2E3 syndrome" OR "NR2E3-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Goldmann-Favre syndrome" OR "Enhanced S-cone syndrome" OR "Retinoschisis with early nyctalopia" OR "enhanced S-cone syndrome 1"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 1 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: ESCS

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1810) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T00:52:45.216Z